WOS: 000286902400010PubMed ID: 21071497Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with beta-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to = 5%) increased serum creatinine, rash and increased alanine aminotransferase. Conclusions Continuous treatment with deferasir...
Heart failure due to myocardial iron overload remains the leading cause of morbidity and mortality i...
WOS: 000357283300009PubMed ID: 25934475Deferasirox (DFX) monotherapy is effective for reducing myoca...
Cardiac iron overload causes most deaths in -thalassemia major. The efficacy of deferasirox in reduc...
PubMed ID: 21071497Background The efficacy of cardiac iron chelation in transfusion-dependent patien...
WOS: 000348846600006PubMed ID: 25345697Long-term controlled studies are needed to inform on the clin...
PubMed ID: 25345697Long-term controlled studies are needed to inform on the clinical benefit of chel...
BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term stu...
Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonst...
WOS: 000275981900009PubMed ID: 19996412Cardiac iron overload causes most deaths in beta-thalassemia ...
INTRODUCTION: The iron chelation therapy in thalassemia major (TM) patients has been demonstrated to...
PubMed ID: 19996412Cardiac iron overload causes most deaths in ß-thalassemia major. The efficacy of ...
Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2*...
WOS: 000335844600010PubMed ID: 24385534Randomized comparison data on the efficacy and safety of defe...
Objectives: To assess the effect of iron chelation therapy with deferasirox on cardiac iron and func...
PubMed ID: 24385534Randomized comparison data on the efficacy and safety of deferasirox for myocardi...
Heart failure due to myocardial iron overload remains the leading cause of morbidity and mortality i...
WOS: 000357283300009PubMed ID: 25934475Deferasirox (DFX) monotherapy is effective for reducing myoca...
Cardiac iron overload causes most deaths in -thalassemia major. The efficacy of deferasirox in reduc...
PubMed ID: 21071497Background The efficacy of cardiac iron chelation in transfusion-dependent patien...
WOS: 000348846600006PubMed ID: 25345697Long-term controlled studies are needed to inform on the clin...
PubMed ID: 25345697Long-term controlled studies are needed to inform on the clinical benefit of chel...
BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term stu...
Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonst...
WOS: 000275981900009PubMed ID: 19996412Cardiac iron overload causes most deaths in beta-thalassemia ...
INTRODUCTION: The iron chelation therapy in thalassemia major (TM) patients has been demonstrated to...
PubMed ID: 19996412Cardiac iron overload causes most deaths in ß-thalassemia major. The efficacy of ...
Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2*...
WOS: 000335844600010PubMed ID: 24385534Randomized comparison data on the efficacy and safety of defe...
Objectives: To assess the effect of iron chelation therapy with deferasirox on cardiac iron and func...
PubMed ID: 24385534Randomized comparison data on the efficacy and safety of deferasirox for myocardi...
Heart failure due to myocardial iron overload remains the leading cause of morbidity and mortality i...
WOS: 000357283300009PubMed ID: 25934475Deferasirox (DFX) monotherapy is effective for reducing myoca...
Cardiac iron overload causes most deaths in -thalassemia major. The efficacy of deferasirox in reduc...